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The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the
effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase
inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial
was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually
active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa.
HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits
for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of
study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of
660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers
(gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In
intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV
incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an
estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall
adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV
seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for
women unable to successfully negotiate mutual monogamy or condom use.
Women are disproportionately affectedby the Acquired ImmunodeficiencySyndrome (AIDS) epidemic in Africa,
the region that accounts for 70% of global burden
of Human Immunodeficiency Virus (HIV) infec-
tion (1). Current HIV prevention behavioral mes-
sages on abstinence, faithfulness, and condom
promotion have had limited impact on HIV inci-
dence rates in women, especially in sub-Saharan
Africa, where young women bear the greatest
HIV burden (2). The search for new technologies
to prevent sexually transmitted HIV infection
over the past three decades has had limited suc-
cess. Only five of 37 randomized controlled trials,
which tested 39 HIV prevention strategies, have
demonstrated protection against sexual transmis-
sion of HIV infection (3). The successful trials
tested medical male circumcision in South Africa
(4), Kenya (5), and Uganda (6) (combined effec-
tiveness in reducing HIV acquisition was 57%),
sexually transmitted infection (STI) treatment in
Tanzania (effectiveness in reducing HIVacquisi-
tion was 42%) (7), and a HIV vaccine combina-
tion in Thailand (effectiveness in reducing HIV
acquisition was 31%) (8). Hence, HIV prevention
technologies that women can use and control
remain a pressing priority (9).
Microbicides are products that can be applied
to the vagina or rectum with the intention of re-
ducing the acquisition of STIs, including HIV.
An effective microbicide has the potential to alter
the trajectory of the global HIV pandemic (10).
Over the last 20 years of microbicide research,
none of the 11 effectiveness trials of six candidate
products have demonstrated meaningful protec-
tion against HIV infection (11).
Tenofovir, an adenosine nucleotide analog
with potent activity against retroviruses (12), was
initially developed and tested as a prophylactic in
monkeys and was subsequently formulated for
oral use as tenofovir disoproxil fumarate (Viread),
which is now widely used for HIV treatment.
Tenofovir’s efficacy in suppressing viral repli-
cation, favorable safety profile, and long half-life
(13) made it an ideal choice as the first anti-
retroviral drug to be formulated as a microbicide
gel. In vitro and in vivo assessments of the 1%
concentration of tenofovir in a gel formulation
have demonstrated its potential as a microbicide
(13). Tenofovir has shown efficacy against viral
challenge in animal models when administered
as pre- or post-exposure prophylaxis (14, 15). In
monkey challenge studies, tenofovir gel has shown
protection with intermittent dosing and with a
single pre-exposure dose (16). In early-stage clin-
ical trials, tenofovir gel was well tolerated in both
HIV-negative andHIV-positive women (17), with
both daily and coitally related use of the gel being
found to be acceptable and safe (18).
The purpose of this study was to assess the
effectiveness and safety of tenofovir gel for the
prevention of HIV infection in women.
Study design and population. Centre for
the AIDS Program of Research in South Africa
(CAPRISA) 004, a two-arm, double-blind, ran-
domized, placebo-controlled trial, was conducted
from May 2007 to March 2010. Women were
enrolled at an urban and a rural clinic in KwaZulu-
Natal, SouthAfrica, but the studywas not designed
to assess the effectiveness of tenofovir in each clin-
ic separately. Urban women were enrolled at the
CAPRISA eThekwini Research Clinic, which is
adjacent to an STI clinic located in the Durban
city center. Rural women were enrolled at the
CAPRISAVulindlela Research Clinic adjacent to
a comprehensive primary health care clinic in
Vulindlela, which is a rural community of ap-
proximately 90,000 people and about 150 km
northwest of Durban. Before the CAPRISA 004
trial, feasibility studies were conducted in order
to assess HIV incidence and sexual behavior at
both sites. Extrapolated HIV incidence rates from
prevalence studies in the urban (19) and rural (20)
sites were 15.6 and 11.2%, respectively. Reported
anal sex rates were substantially lower at these
two sites than we had observed in previous mi-
crobicide trials (21) in female sex workers in this
region. Data from these feasibility studies were
used as the basis for selecting these sites for the
trial, as well as for the design and sample size
calculations for the CAPRISA 004 trial.
HIV-negative women, from 18 to 40 years
old, who were sexually active (defined as having
engaged in vaginal sex at least twice in the 30
days before screening), not pregnant, and using a
nonbarrier form of contraceptive were eligible for
enrollment. Participants who had a history of ad-
verse reactions to latex, planned to either travel
away from the study site for more than 30 con-
secutive days, relocate away from the study site,
become pregnant, or enroll in any other behav-
ioral or investigational product study were ex-
cluded. Participants who had a creatinine clearance
of <50 ml/min (22), had evidence of genital deep
epithelial disruption, had in the past year par-
ticipated in any research related to any vaginally
applied product or products, or had an untreated
STI or reproductive tract infection were also ex-
cluded. Women who met eligibility criteria and
demonstrated adequate understanding of the trial
(through a comprehension checklist) were en-
rolled after providing written informed consent.
From May 2007 to January 2009, 2160 women
were screened and 1085 were enrolled, of whom
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889 were included in the analysis (Fig. 1).
Further information on the enrollment process
and exclusions can be found in (23).
Enrolled women were randomly assigned in
equal proportions to one of two study arms:
tenofovir gel or placebo gel. Tenofovir gel com-
prised 40 mg of 9-[(R)-2-phosphonomethoxy)
propyl]adenine monohydrate (PMPA) in a solu-
tion of purified water with edetate disodium, cit-
ric acid, glycerin, methylparaben, propylparaben,
and hydroxyethycellulose (HEC). The placebo
gel was the “universal” HEC placebo gel, which
has been shown to have minimal anti-HIV ac-
tivity (24). Tenofovir and placebo gels appeared
identical and were dispensed in the same pre-
filled vaginal applicators with identical packaging.
A coitally related dosing strategywas selected
to achieve high adherence on the basis of in-depth
consultations with the communities involved. Sex-
ual behavior data showed that women in the key
study population had infrequent high-risk sexwith
migrant partners.Monkey challenge data and peri-
natal transmission studies informed the timing
of doses in relation to sex. The “before and after”
sex dosesweremodeled on the timingof nevirapine
in its proven strategy for preventing mother-to-
child HIV transmission (25). Women were re-
quested to insert one dose of gel within 12 hours
before sex and a second dose of gel as soon as
possible within 12 hours after sex and no more
than two doses of gel in a 24-hour period. Hence,
the dosing strategy is referred to as “BAT24.”
The latter restriction was imposed because of the
lack of human safety data on more than two doses
of gel per day.
Gel adherence was defined as the estimated
proportion of reported sex acts covered by two
gel doses and calculated for each woman by di-
viding half the number of returned used applica-
tors each month by the number of reported sex
acts that month. Applicators that were not returned
were regarded as unused for the purposes of cal-
culating adherence. When we conducted a sensi-
tivity analysis treating unreturned applicators as
used, the results did not change materially. The
median of each woman’s monthly adherence es-
timates was assigned as her overall gel adherence.
This approach assumed that every reported sex
act used two doses of gel. Although this assump-
tion was not always applicable, adjusting for mul-
tiple sex acts within 24 hours made no material
difference.
At enrollment and monthly follow-up visits,
participants were provided with comprehensive
HIV prevention services (HIV pre- and post-test
counseling, HIV risk reduction counseling, con-
doms, and STI treatment), reproductive health
services, and assigned study gel.
Participants were requested to return their
used (from October 2007 onward) and unused
applicators at every visit. Each month, the ap-
plicators returned by women as used and unused
were counted, reconciled against the number dis-
pensed, and thereafter discarded, in accordance
with standard requirements for medical waste.
A comprehensive adherence support program
assisted participants with the mechanics of appli-
cator use, timing and dosing, avoidance of gel
sharing, and incorporation of gel use into their
daily routines. FromOctober 2008, individualized
motivational interviewing (26, 27) was introduced
to assist participants so as to overcome obstacles
to gel use and set goals for optimal adherence in
the upcomingmonth. This included individualized
adherence support and counseling, customized on
the previous month’s experience of gel use, which
was provided throughout the study. The women
in this study were specifically and repeatedly
counseled to only use the gel vaginally, and the
lack of safety with rectal use was highlighted.
Each participant had monthly HIV and urine
pregnancy testing [QuickVueOne-Step hCGUrine
Test (Quidel Corporation, San Diego, California)]
performed before gel was dispensed. Because of
a lack of pregnancy safety data, gel use was tem-
porarily discontinued after a positive pregnancy
test and resumedwhen the pregnancy test returned
to negative. Self-reported data on gel use and sex-
ual frequency during the last 30 days were col-
lected at monthly visits, together with gel and
condomuse on the day of the last sex act, bymeans
of a brief interviewer-administered questionnaire.
Two months after study exit, participants attended
a posttrial visit to assess HIV status and safety
after product withdrawal.
Drug safety was assessed at every study visit
by evaluating, grading, and recording adverse
events experienced by participants. Participants
underwent quarterly pelvic examinations and, if
needed, colposcopy. Serology was performed for
hepatitis B virus [Abbott Architect C8200 (Abbott
Laboratories, Detroit, Michigan)] and herpes sim-
plex type 2 virus [Kalon Enzyme Immunoassay
(Kalon Biologicals, Ashgate, UK)]. Hematological,
hepatic, and renal abnormalities were assessed at
study months 3, 12, and 24; additionally when clin-
ically indicated; and at study exit. Adverse events
were graded for severity via theDivision of AIDS
Table for Grading Adult and Pediatric Adverse
Events, 2004. Product use was temporarily discon-
tinued for an adverse event at the discretion of theFig. 1. Screening, enrollment, randomization, and follow-up of the study participants.


































study clinician. The trial (NCT00441298) was ap-
proved by the University of KwaZulu-Natal’s Bio-
medical Research Ethics Committee (E111/06),
Family Health International (FHI)’s Protection of
Human Subjects Committee (9946), and the South
African Medicines Control Council (20060835).
HIV, viral load, and genotypic resistance
assays. Two HIV rapid tests, Determine HIV 1/2
(Abbott Laboratories, Chicago, Illinois) and Uni-
Gold Recombigen® HIV test (Trinity Biotech,
Wicklow, Ireland), were performed at each study
visit. Participants with concordantly positive, dis-
cordant, or indeterminate results were assessed for
possible seroconversion by means of two sepa-
rate RNApolymerase chain reaction (PCR) [Roche
Cobas TaqMan HIV-1 Monitor v1.0 (Roche Diag-
nostics, Branchburg, New Jersey)] assays, about
1 week apart. When HIV seroconversion was es-
tablished, product usewas discontinued, andwom-
en were referred to local AIDS treatment services,
including the CAPRISA AIDS Treatment Pro-
gram, which provides free antiretroviral therapy.
Stored plasma, available from prior study visits
by each seroconverter, was tested by means of
RNAPCR so as to identify thewindow period for
HIV infection (RNA PCR–positive but rapid HIV
test–negative) at prior visits. By protocol, only eli-
gibly enrolled women with HIV infection during
study follow-up, as confirmed by two independent
RNAPCR results, were defined as HIVendpoints.
Participants in the HIV window period at study
exit were included as HIV endpoints if seroposi-
tivity was confirmed after the study. Thus, HIV
infections were categorized as follows: (i) HIVend-
points, (ii) HIV infections not meeting the pro-
tocol definition for anHIVendpoint (did not have
the two independent RNAPCR tests), (iii) window
period HIV infections at enrollment (infected be-
fore study entry), (iv) posttrial HIV infections (in-
fected after study exit), and (v)HIVinfections among
women who were enrolled and later found to be
ineligible (23).
Tenofovir resistance testing and Western Blot
[Genetics systemsHIV-1Western Blot kit (Bio-Rad
Laboratories, Hercules, California)] were performed
at the post-seroconversion visit. The HIV-1 pol
gene was population sequenced by means of a cer-
tified (28) in-house assay. Viral RNAwas extracted,
and a 1.7-kb fragment spanning the pol gene was
amplified by means of nested PCR with the Ex-
pand Long Template PCR System (Roche Diag-
nostics), as described previously (28). PCRproducts
were sequenced (codons 1 to 99 of protease and
codons 1 to 350 of reverse transcriptase) by using a
BigDyeTerminator v3.1 cycle sequencing kit and an
ABI 3130XL DNA sequencer (Applied Biosys-
tems, Foster City, California). Consensus sequences
were aligned and manually edited by using the Se-
quencher version 4.5 program (GeneCodes, Ann
Arbor, Michigan) and submitted to the Stanford
UniversityHIVDrugResistance Database (http://
hivdb.stanford.edu) to identify mutations.
Statistical analyses. In this endpoint-driven
trial, participants were followed until 92 HIV
infections were observed, providing 90% power
to detect a 50% effect (two-sided a = 0.05). Orig-
inally, the study was designed with 80% power.
Before their first data review, the Data Safety and
Monitoring Board (DSMB) ratified a change to
90% power adjusted for two preplanned interim
reviews, with stringent stopping guidelines.
Upon enrollment, a participant was assigned a
sequential identification number, which corre-
sponded to a unique envelope (accessible only to
each study site pharmacist) that allocated her
randomly, by using permuted block random-
ization of sizes 12 and 18, with no stratification, to
one of six codes. The three codes assigned ran-
domly to each of tenofovir and placebo gels were
held in confidence by the product manufacturer
and independent DSMB statistician.
The primary intent-to-treat analysis was based
on a log-rank test, stratified by site. Duration of
time on study was calculated from randomization
to estimated date of HIV infection or date of
withdrawal, whichever occurred first. A Poisson
distribution was assumed for confidence intervals
(CIs) of incidence rates and incidence rate ratios
(IRRs). Fisher’s exact test and the unpaired t test/
Wilcoxon two-sample test were performed where
appropriate. Proportional hazards regressionmodels
were used to calculate hazard ratios while adjust-
ing for potentially important covariates. All reported
P values are two-sided, and all CIs are 95%. The
statistical analysis was performed using SAS (SAS
Institute, Cary, North Carolina) version 9.1.3.

















Mean age (years) 23.3 25.1 <0.001 24.2 23.6 0.131
Monthly income <1000
South African rand
86.1% 69.1% <0.001 81.1% 80.4% 0.799
Married 6.5% 3.6% 0.085 5.8% 5.4% 0.884
Stable partner 77.0% 93.1% <0.001 87.6% 88.5% 0.756
Sexual behavior
Mean age sexual debut 17.3 17.7 0.014 17.4 17.4 0.782
Mean number sexual partners
(lifetime)
2.1 6.0 <0.001 3.0 3.6 0.780
Mean age of oldest partner
(past 30 days)
26.4 29.6 <0.001 27.7 27.1 0.299
Reported sex in the past
7 days
58.9% 68.3% 0.007 63.6% 60.1% 0.301
Always use condom during sex 22.9% 42.8% <0.001 28.8% 29.5% 0.825
New partner (past 30 days) 0.5% 2.5% 0.014 1.3% 0.9% 0.753
Anal sex (past 30 days) 0.5% 0.4% 1.000 0.4% 0.5% 1.000
HSV-2 prevalence 47.6% 59.6% 0.001 53.5% 49.2% 0.202
Contraception
Injectable 83.1 79.9 0.606* 80.7% 83.6% 0.288*
Oral 14.6 17.6 16.4% 14.6%
Tubal ligation 2.1 2.5 2.9% 1.6%
Hysterectomy 0.2 0.0 0 0.2%
*P value applicable to comparison for all forms of contraception.


































Results. A total of 611 rural and 278 urban
women met eligibility criteria, were enrolled, and
followed up, for a total of 1341 women-years
(mean = 18 months) and an overall study re-
tention rate of 94.8%. Rural women were young-
er and poorer, with fewer lifetime sexual partners,
and had lower sexual frequency and lower con-
dom use (Table 1). At enrollment, there were no
significant differences in the demographic char-
acteristics and sexual behavior of women in the
tenofovir (n = 445 women) and placebo (n = 444
women) gel arms (Table 1).
HIV incidence and effectiveness. The teno-
fovir and placebo gel arms had 38 and 60 HIV
endpoints, respectively. The HIV incidence rate
in the tenofovir gel armwas 5.6 per 100 women-
years (CI, 4.0 and 7.7) compared with 9.1 per 100
women-years (CI, 6.9 and 11.7) in the placebo gel
arm (IRR = 0.61; CI, 0.40 and 0.94; P = 0.017).
HIV infection trends (Fig. 2) show that the
tenofovir gel effect was evident soon after initia-
tion of gel use. The steadily declining HIV inci-
dence rates in placebo gel arm were 11.2, 10.5,
10.2, 9.4, and 9.1 per 100 women-years after
follow-up for 6, 12, 18, 24, and 30 months, re-
spectively (Fig. 2). In contrast, the HIV inci-
dence rate in the tenofovir gel arm remained in
a narrow range between5.2 and6.0 per 100women-
years during the study. The HIV incidence rate
in the tenofovir gel arm, when compared with
the placebo gel arm, was 50% (P = 0.007) lower
after 12months of follow-up and 40% (P= 0.013)
lower after 24 months of follow-up (Fig. 2).
After adjusting for baseline covariates includ-
ing, age, site, anal sex history, contraceptivemethod,
HSV-2 antibody status, and condom use, the hazard
ratiowas 0.63 (CI, 0.42 and 0.94;P= 0.025). All 98
Fig. 2. Kaplan-Meier estimates of cumulative probability of HIV infection in the tenofovir and placebo gel
arms. The table provides the cumulative number of HIV endpoints, corresponding HIV incidence rates, and
effectiveness of tenofovir gel for each additional 6 months of follow-up.













Overall effectiveness of tenofovir gel
HIV endpoints 38/680.6 60/660.7 889 5.6 (4.0, 7.7) 9.1 (6.9, 11.7) 0.61 39% 6, 60 0.017
Site-specific effectiveness
Rural 25/484.7 42/461.2 611 5.2 (3.3, 7.6) 9.1 (6.6, 12.3) 0.57 43% 5, 67 0.023
Urban 13/195.9 18/199.5 278 6.6 (3.5, 11.3) 9.0 (5.3, 14.3) 0.74 26% -59, 67 0.380
HIV endpoints by levels of adherence*
High adherers
(>80% gel adherence)
11/259.2 25/269.4 336 4.2 (2.1, 7.6) 9.3 (6.0, 13.7) 0.46 54% 4, 80 0.025
Intermediate adherers
(50–80% adherence)
10/159.8 10/99.7 181 6.3 (3.0, 11.5) 10.0 (4.8, 18.4) 0.62 38% -67, 77 0.343
Low adherers
(<50% gel adherence)
16/258.5 25/290.6 367 6.2 (3.5, 10.1) 8.6 (5.6, 12.7) 0.72 28% -40, 64 0.303
Sensitivity analyses
HIV endpoints plus
HIV infection not meeting
protocol definition
39/680.6 60/660.7 889 5.7 (4.1, 7.8) 9.1 (6.9, 11.7) 0.63 37% 4, 59 0.023
HIV endpoints
plus ineligibly enrolled
40/720.1 63/698.6 1075 5.6 (4.0, 7.6) 9.0 (6.9, 11.5) 0.62 38% 7, 60 0.015
HIV endpoints plus women
with post-trial infection
39/680.6 64/660.7 889 5.7 (4.1, 7.8) 9.7 (7.5, 12.4) 0.59 41% 11, 61 0.015
Per protocol analysis† 32/589.2 53/575.4 889 5.4 (3.7, 7.7) 9.2 (6.9, 12.0) 0.59 41% 7, 63 0.017
All HIV infections‡ 43/720.1 76/698.8 1085 6.0 (4.3, 8.0) 10.9 (8.6, 13.6) 0.55 45% 19, 63 0.003
Adjusted analysis§ 38 60 889 Hazard ratio = 0.63 37% 6, 58 0.025
*Adherence could not be calculated for the five women who reported no sex during their follow-up in the study. †Excludes all visits after 3 month’s interruption of drug supply. ‡All HIV
infections = protocol-defined HIV endpoints (n = 98 women) + HIV infection not meeting protocol definition (n = 1 woman who did not have 2 RNA PCR results) + HIV infections among
ineligibly enrolled women (n = 5 women) + posttrial HIV infections (n = 5 women) + window period HIV infections in eligible women (n = 8 women) + window period HIV infections in
ineligibly enrolled women (n = 2 women). §Adjusted for the following baseline covariates: age, site, parity, number of sexual partners (past 30 days), presence of STI, anal sex,
contraceptive method, HSV-2 antibody status, and condom use; HSV-2 status is indeterminate in four women and missing in five women.


































HIV endpoints were Western Blot–positive. One
additional HIV infection did not meet the protocol
endpoint requirement of two independent RNA
PCR results. There were five HIV infections among
ineligibly enrolledwomen, 10 window-period HIV
infections (two among ineligibly enrolled wom-
en), and five posttrial HIV infections. Sensitivity
analyses (Table 2), which include these addition-
al HIV infections, do not differ appreciably from
the overall 39% level of effectiveness.
Gel adherence and sexual behavior. Over
the entire duration of the study, 181,340 applicators
were dispensed, and 95.2% of these were returned.
Each month, study participants returned an aver-
age of 6.0 used applicators and reported a mean
of 5.0 sex acts. Coital frequency, gel adherence,
and condom use during the trial were similar in
the tenofovir and placebo gel arms. Gel accept-
ability was high; 97.4% of the study participants
found the gel to be acceptable, and 97.9% indi-
cated that they would use it if it prevented HIV.
Five women reported having no sex during
follow-up in the study.Adherence estimates based
on applicator returns for the remaining 884 wom-
en indicate that, on average, 72.2% (median =
60.2%) of self-reported sex acts in the last 30
days were covered by two doses of gel. In the 336
high gel adherers, HIV incidence was 54% lower
(IRR = 0.46; CI, 0.20 and 0.94; P = 0.025) in the
tenofovir gel arm (Table 2). In intermediate gel ad-
herers and low gel adherers, the HIV incidence
reductionwas 38%(P=0.343) and28%(P=0.303),
respectively. The mean number of sex acts in the
high, intermediate, and low gel adherers was 3.2,
5.0, and 6.7 per month, respectively.
Over the 30 months of follow-up, reported
coital frequency declined steadily (Fig. 3), from
7.2 sex acts per month in the first 6 months to 3.1
sex acts per month in months 18 to 24 (P <
0.001). In women who did not acquire HIV,
overall median gel adherence was 61.3%, in-
creasing from 55.0% in the first 6 months to
75.0% in months 18 to 24 (P < 0.001). In HIV
seroconverters, overall median adherence (until
product discontinuation after HIV infection) was
59.2%, ranging from 56.9% in the first 6 months
to 61.3% inmonths 18 to 24 (P= 0.735). Overall,
condoms were reportedly used in 80.3% of sex
acts, increasing from 78.5% in the first 6 months
to 84.3% in months 18 to 24 (P < 0.001) (Fig. 3).
Safety and pregnancy outcomes. There were
4692 adverse events reported during the study,
with 94.3% (838 out of 889) of the study partic-
ipants reporting at least one adverse event. Ad-
verse event rates were 3.55 per women-year in the
tenofovir and 3.44 per women-year in the placebo
gel arms (P = 0.265). Women in the tenofovir gel
arm reported more instances of diarrhea (Table 3)
than those using placebo gel (16.9 versus 11.0%,
P = 0.015). There were 39 serious adverse events,
including one death. In the 37 hepatitis B virus
carriers (20 randomized to tenofovir gel and 17 to
placebo gel), there were two cases of “hepatic
flares” (alanine aminotransferase > 5 times the
upper limit of normal) in each arm. Further infor-
mation on grading of the hepatic, renal, and bone-
adverse events can be found in (23).
Five participants discontinued gel use for a
total of 1.04 women-years because of adverse
events; four were due to genital findings, and one
was due to congestive cardiac failure.
The overall pregnancy rate was 4.0 per 100
women-years: 3.2 per 100 women-years in the
tenofovir arm and 4.7 per 100 women-years in
the placebo arm (P= 0.183) (Table 3). At the time
of analysis, there were six ongoing pregnancies,
and 58.3% of the remaining 48 pregnancies had
resulted in a full-term live birth. There were no
significant differences in pregnancy outcomes by
study arm, and there were no congenital anom-
alies. A total of 20.9 women-years of follow-up
occurred while women were not using gel be-
cause of pregnancy.
Viral load and tenofovir resistance. Themean
log HIV viral load at the time when HIV sero-
conversion was identified was 4.65 [interquartile
range (IQR), 4.04 to 5.39] and 4.30 (IQR, 3.56
to 5.17) log copies per milliliter in the tenofovir
gel arm (n = 38 HIV seroconverters) and placebo
gel arm (n = 60HIV seroconverters), respectively
(P = 0.147).
It is estimated that the HIV seroconverters
were exposed to gel episodically for about 3 to 4
weeks after infection and the resistance assays
(n = 35 HIV seroconverters) were performed on
average 20 weeks after the estimated date of in-
fection. There were no tenofovir-related resist-
ance mutations (K65R or K70E) detected, and
none of the women had thymidine analog mu-
tations (M41L, L210W, T215Y/F, D67N, K70R,
and K219Q/E) or mutations that confer multiple–
nucleoside reverse transcriptase inhibitor resist-
ance (29).
Discussion. Tenofovir gel reduced HIV in-
fection by an estimated 39%. The protective ef-
fect of coitally related tenofovir gel use was
evident soon after initiation and peaked at 50%
after 12 months of gel use. This protective effect
is evident irrespective of sexual behavior, con-
dom use, herpes simplex type 2 virus infection,
or urban/rural differences. A trend of higher ef-
fectiveness was observed as gel adherence im-
proved; high adherers had a 54% lower HIV
incidence rate in the tenofovir gel arm.
The observed level of effectiveness is depen-
dent on both the efficacy of the product and the
participants’ willingness and ability to use it as
prescribed. Inadequate adherence is the most se-
rious challenge to obtaining an accurate estimate
of product efficacy (30). To address this, we im-
plemented an intensive adherence support pro-
gram with motivational strategies that depended
on reliable measurement of adherence. Monitor-
ing of this key behavior in the trial included an
objective count of used and unused applicators
returned each month and did not rely solely on
self-reported use. Despite this adherence program
and high gel acceptability, about 40% of the
women in this study had below 50% gel ad-
herence. Future trials will need to place greater
emphasis on enhancing and objectively measur-
ing adherence, in light of its substantial influence
on the trial outcome.
In this study population, women with the
highest gel adherence tended to have the lowest
reported coital frequency. Despite their lower
coital frequency, these women had HIV inci-
dence rates comparable (in the placebo gel arm)
with those in women with much higher coital fre-
quencies, highlighting the importance of infre-
quent but very high-risk sex with migrant men.
The impact of coitally related tenofovir gel was
substantial in this group, indicating its potential to
alter the course of the HIV epidemic in southern
Africa, where young women engaging in sexwith
Fig. 3. Trends in coital frequency, condom use, and gel use (gel use by HIV status) in relation to
duration of follow-up.


































migrant men is the key driver in the spread of HIV
infection (31). On a cautionary note, the effective-
ness of coitally related tenofovir gel appeared to
decline after 18 months; reasons for this are un-
clear, and factors, including the possibility of de-
clining number of gel applications and/or adherence
over time, need further investigation.
HIV incidence rates observed in this study
population were high because KwaZulu-Natal
province is at the epicenter of South Africa’s
“explosive” HIV epidemic (32). Although the
women in the tenofovir gel arm had a substan-
tially lower HIV incidence rate than that of the
placebo arm, they still had an unacceptably high
HIV incidence rate, consistently above 5 per 100
women-years. This highlights the need to seek
higher levels of adherence and effectiveness with
tenofovir gel and to develop other effective pre-
vention strategies for use in combination with
tenofovir gel. Encouragingly, there was no evi-
dence of risk compensation (33), in which indi-
viduals increase their HIV risk by reducing their
use of proven prevention modalities, such as con-
doms, in favor of less effective or unproven pre-
vention strategies. Instead, we observed declining
HIV incidence rates in the placebo gel arm. This
may have been due to their declining coital fre-
quency and increasing condom use. However,
the consistently high levels of self-reported con-
dom use in the last sex act need to be interpreted
cautiously because these may be affected by in-
accurate recall and may be indicative of condom
use in only the last sex act and not all sex acts.
We found no empirical evidence for the the-
oretical concern that tenofovir gel maymaskHIV
infection and that withdrawal of tenofovir gel use
after study exit may lead to the unmasking of
these infections.
Coitally related tenofovir gel usewas safe. There
were no increases in renal, hepatic, pregnancy-
related, or genital-adverse events. The increased
risk of diarrhea in women using tenofovir gel
may possibly have been due to a local tenofovir
effect; further investigation is needed to establish
the mechanism for this observed adverse effect.
The reported cases of diarrhea were mild and
self-limiting, rarely requiring medication.
There was no renal toxicity—the most impor-
tant tenofovir-related safety concern (34)—although
the study excluded women with compromised
creatinine clearance at enrollment. Increases in
hepatic flares, which have been reported upon
cessation of oral tenofovir use in hepatitis B–
infected individuals (35), was not observed in
this study, possibly because of the low systemic
absorption of tenofovir from the gel formulation
(17). No safety concerns were identified in the 22
Table 3. Adverse events and other safety markers in the CAPRISA 004 tenofovir gel trial.
Tenofovir gel Placebo gel
P valueEvents/participants/
(percent with ≥ 1 event)
Events/participants/
(percent with ≥ 1 event)
Number of adverse events 2419/423/(95.1) 2273/415/(93.5) 0.32
Deaths 0/0/(0) 1/1/(0.2) 0.50
Serious adverse events:
total serious adverse events
23/21/(4.7) 16/16/(3.6) 0.50
Pregnancy-related serious adverse events 8/8/(1.8) 8/8/(1.8) 1.00
Grade 3* adverse events 19/15/(3.4) 18/16/(3.6) 0.86
Grade 4* adverse events 4/4/(0.9) 4/3/(0.7) 1.00
Common adverse events
Influenza 365/216/(48.5) 314/220/(49.5) 0.79
Vaginal discharge 203/156/(35.1) 239/156/(35.1) 1.00
Headache 126/93/(20.9) 133/102/(23.0) 0.53
Urinary tract infection 135/100/(22.5) 120/93/(20.9) 0.63
Diarrhea and gastrointestinal infections 91/75/(16.9) 65/49/(11.0) 0.02
Upper respiratory tract infections 162/114/(25.6) 145/100/(22.5) 0.31
Genital adverse events
Disrupted epithelium, e.g., genital ulceration 18/18/(4.0) 14/13/(2.9) 0.47
Intact epithelium, e.g., erythema 48/41/(9.2) 42/33/(7.4) 0.40
Urogenital symptoms (such as menorrhagia) 312/210/(47.2) 394/238/(53.6) 0.06
Vaginal candidiasis 156/114/(25.6) 187/130/(29.3) 0.23
Other 182/131/(29.4) 176/123/(27.7) 0.60
Laboratory parameters: any abnormality after randomization
Hepatic
Aspartate aminotransferase (AST) 29/21/(4.7) 36/29/(6.5) 0.25
Alanine transaminase (ALT) 42/33/(7.4) 50/40/(9.0) 0.38
Renal
Raised creatinine 3/3/(0.7) 1/1/(0.2) 0.62
Low potassium 119/95/(21.3) 99/83/(18.7) 0.36
Abnormal sodium 54/48/(10.8) 43/41/(9.2) 0.50
Hematological
Anemia 52/34/(7.6) 46/29/(6.5) 0.60
Neutropenia 19/16/(3.6) 13/11/(2.5) 0.44
Bone
Low phosphate 79/62/(13.9) 65/51/(11.5) 0.31
Abnormal calcium 16/15/(3.4) 14/13/(2.9) 0.85
Fractures 5/4/(0.9) 2/2/(0.5) 0.69
Pregnancy rate per 100 women-years 3.2 4.7 0.18
Proportion of pregnancies resulting in live births 66.7 51.9 0.38
*Grade 3 and 4 adverse events refer to the grading for severity according to the Division of AIDS Table for Grading Adult and Pediatric Adverse Events, 2004 (http://rsc.tech-res.com/
safetyandpharmacovigilance/).


































women exposed to tenofovir gel in early preg-
nancy, providing further evidence to support the
analysis of the Antiretroviral Pregnancy Register
(36), which showed no increases in congenital
anomalies. No tenofovir-related resistance was
found in the 35 women exposed to tenofovir gel
early in acute HIV infection. Further studies to
identify tenofovir resistance at earlier time points
after infection, in both the genital and systemic
compartments, are needed. Coitally related teno-
fovir gel use showed no impact on viral load in
HIV seroconverters.
This test-of-concept study had several limi-
tations; the relatively small sample size and the
small number of study sites restrict the broad
generalizability of the results. The study’s ad-
herence program needed to attain higher and sus-
tained levels of adherence. The co-enrollment
challenge was a setback at the urban site. It did
not, however, affect the estimated effectiveness
of tenofovir gel when infections in co-enrolled
women were included in the analysis. It is not
possible to derive from this study any conclu-
sions on the safety and effectiveness of tenofovir
gel for anal sex. Similarly, it is not possible to
make any conclusions on the effectiveness of
tenofovir gel in relation to the timing of gel ap-
plications because when gel was applied, BAT24
was usually followed.
Currently, there are five large-scale trials as-
sessing oral pre-exposure prophylaxis with teno-
fovir or tenofovir-emtricitabine (37) in men who
have sex with men, intravenous drug users, and
heterosexual men and women. One of these, the
Microbicide Trials Network (MTN) 003 trial (38),
is assessing the effectiveness of daily tenofovir gel
for HIV prevention. This critically important study
will provide urgently needed evidence on wheth-
er more frequent dosing can improve adherence
and effectiveness of tenofovir gel without com-
promising safety. Additional studies are needed
to corroborate the findings of the CAPRISA 004
trial and to assess the safety, effectiveness, ad-
herence, and cost advantages or disadvantages of
coitally related tenofovir gel as compared with
daily tenofovir in either the gel or oral formula-
tion for HIV prevention in women.
Conclusion. Coitally related tenofovir gel ap-
pears safe and effective in preventing HIV in-
fection. Once these promising findings have been
corroborated, this antiretroviral microbicide could
potentially fill an important HIV prevention gap,
especially for women unable to successfully ne-
gotiate mutual monogamy or condom use.
References and Notes
1. UNAIDS, WHO, AIDS Epidemic Update (Joint United
Nations Programme on HIV/AIDS and World Health
Organization, Geneva, 2009).
2. S. S. Abdool Karim, G. J. Churchyard, Q. Abdool Karim,
S. D. Lawn, Lancet 374, 921 (2009).
3. N. S. Padian, S. I. McCoy, J. E. Balkus, J. N. Wasserheit,
AIDS 24, 621 (2010).
4. B. Auvert et al., PLoS Med. 2, e298 (2005).
5. R. C. Bailey et al., Lancet 369, 643 (2007).
6. R. H. Gray et al., Lancet 369, 657 (2007).
7. H. Grosskurth et al., Lancet 346, 530 (1995).
8. S. Rerks-Ngarm et al.; MOPH-TAVEG Investigators,
N. Engl. J. Med. 361, 2209 (2009).
9. Z. A. Stein, Am. J. Public Health 80, 460 (1990).
10. C. Watts, P. Vickerman, AIDS 15, S43 (2001).
11. S. S. Abdool Karim, C. Baxter, HIV Ther. 3, 3 (2009).
12. E. De Clercq, Biochem. Pharmacol. 73, 911 (2007).
13. L. C. Rohan et al., PLoS ONE 5, e9310 (2010).
14. R. A. Otten et al., J. Virol. 74, 9771 (2000).
15. C.-C. Tsai et al., Science 270, 1197 (1995).
16. U. M. Parikh et al., J. Virol. 83, 10358 (2009).
17. K. H. Mayer et al.; HPTN 050 Protocol Team, AIDS 20,
543 (2006).
18. S. L. Hillier, paper presented at the Microbicide 2008,
New Delhi, India, 2008.
19. A. B. Kharsany, Q. A. Karim, S. S. Abdool Karim, AIDS
Care 22, 533 (2010).
20. A. B. Kharsany et al., HIV Med.; published online 17 May
2010.
21. L. Van Damme et al.; COL-1492 Study Group, Lancet
360, 971 (2002).
22. D. W. Cockcroft, M. H. Gault, Nephron 16, 31 (1976).
23. Materials and methods are available as supporting
material on Science Online.
24. D. Tien et al., AIDS Res. Hum. Retroviruses 21, 845
(2005).
25. J. B. Jackson et al., Lancet 362, 859 (2003).
26. R. A. Ferrer, K. M. Morrow, W. A. Fisher, J. D. Fisher, AIDS
Care 22, 997 (2010).
27. W. R. Miller, S. Rollnick, Motivational Interviewing
(Guilford, New York, 1991).
28. V. Pillay et al., Antivir. Ther. 13 (suppl. 2), 101 (2008).
29. Single-letter abbreviations for the amino acid
residues are as follows: A, Ala; C, Cys; D, Asp; E,
Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M,
Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr;
V, Val; W, Trp; and Y, Tyr. In the mutants, other amino
acids were substituted at certain locations; for example,
K65R indicates that lysine at position 65 was replaced
by arginine.
30. S. W. Lagakos, A. R. Gable, Eds., Methodological
Challenges in Biomedical HIV Prevention Trials (National
Academy of Sciences, Washington, DC, 2008).
31. M. N. Lurie et al., AIDS 17, 2245 (2003).
32. Q. Abdool-Karim, S. S. Abdool-Karim, Int. J. Epidemiol.
31, 37 (2002).
33. M. M. Cassell, D. T. Halperin, J. D. Shelton, D. Stanton,
BMJ 332, 605 (2006).
34. B. Schaaf, S. P. Aries, E. Kramme, J. Steinhoff, K. Dalhoff,
Clin. Infect. Dis. 37, e41 (2003).
35. M. Crane et al., J. Infect. Dis. 199, 974 (2009).
36. R. S. Brown, D. Goodwin, S. Zhang, E. Fagan, paper
presented at the 13th International Symposium on Viral
Hepatitis and Liver Disease (ISVHLD), Washington, DC, 20
to 24 March 2009.
37. AVAC, Pre-Exposure Prophylaxis (PrEP), available at www.
avac.org/ht/d/sp/i/262/pid/262/cat_id/458/cids/453,458
(2010) (accessed 12 June 2010).
38. Microbicide Trials Network, “Phase 2B safety and
effectiveness study of tenofovir 1% gel, tenofovir
disoproxil fumarate tablet, and emtricitabine/tenofovir
disoproxil fumarate tablet for the prevention of HIV
infection in women,” available at www.mtnstopshiv.org/
node/70 (2010) (accessed 12 June 2010).
39. We pay tribute to the women who participated in
this trial; their dedication and commitment made this
study possible. We thank the Health Department
of the City of Durban, the traditional leadership
of Vulindlela, specifically N. Sondelani Zondi and
N. Nsikayezwe Zondi, and members of the Community
Advisory Boards at the Vulindlela and eThekwini Research
Clinics. Q.A.K. is the co-principal investigator of the
HIV Prevention Trials Network (HPTN) Prevention
Leadership Group [NIH/National Institute of Allergy
and Infectious Diseases (NIAID) U01 AI068619].
S.S.A.K. was the protocol chair of the HPTN 035 trial,
which was supported by NIH (grants U01AI46749 and
U01AI068633). The other authors have no financial
conflicts of interest. By arrangement with Gilead
Sciences and CONRAD, LIFElab—a biotechnology
center of the South African Department of Science
and Technology—acquired a voluntary nonexclusive
royalty-free license for tenofovir gel for low-cost
distribution in Africa. The CAPRISA 004 Tenofovir gel
trial was supported by CAPRISA, the United States
Agency for International Development (USAID), FHI
(cooperative agreement GPO-A-00-05-00022-00 and
contract 132119), and LIFElab. Support from CONRAD
for the product manufacturing and packaging, as well
as support from Gilead Sciences for the tenofovir used
in the production of gel, is gratefully acknowledged.
We thank NIH’s Comprehensive International Program
of Research on AIDS (CIPRA grant AI51794) and the
Columbia University–Southern African Fogarty AIDS
International Training and Research Programme
(AITRP grant D43TW00231) for the research infrastructure
and training that made this trial possible. The Trial
Oversight Committee included Q.A.K., S.S.A.K. (CAPRISA),
L. Claypool, J. Manning, J. Spieler (USAID), H. Gabelnick
(CONRAD), B. Okole, C. Montague (LIFElab), J. Rooney
(Gilead Sciences), W. Cates, L. Dorflinger, and D.T. (FHI).
The study monitors were S. Combes, C. Katz, L. McNeil,
and A. Troxler and the DSMB members were E. Bukusi,
M. Chen (independent statistician), K. Dickson, C. Lombard,
K. Mayer (chair), and S. Self.
The CAPRISA 004 Trial Group includes (in alphabetical
order)
Principal Investigators: Q. Abdool Karim and S. S. Abdool
Karim
Site Directors: J. A. Frohlich, A. B. M. Kharsany, and K. P.
Mlisana
Project Coordinators: C. Baxter and L. E. Mansoor
Site Coordinators: N. A. Arulappan and S. Maarschalk
Assistant Site Coordinators: H. Humphries, G. Parker, J.
Richards, and J. Upton
Study Gynecologist: S. Sibeko
Clinicians: B. Mdluli, N. Miya, L. Mtongana, N. Naicker, Z.
Omar, and D. Sokal (FHI)
Nurses:D.D. Chetty, F. Dlamini, S. D. Gumede, Z. Gumede, N. E.
Khambule, N. Langa, B. T. Madlala, N. Madlala, N. Mkhize, Z. L.
Mkhize, M. Mlotshwa, C. Ndimande, N. Ngcobo, C. Ntshingila,
B. Phungula, and T. E. Vumase
Counselors: N. B. Biyela, N. Dladla, T. Dlamini, C. T. Khwela,
N. Mayisela, M. R. Mlaba, J. Mchunu, Z. Msimango, D. Nkosi,
and T. Shange
Pharmacists: L. Chelini, T. N. Gengiah, A. Gray, B. Maharaj,
G. I. Masinga, A. Naidoo, and M. Upfold
Pharmacist’s Assistants: B. Moodley, Y. Naidoo, C. Ngcobo,
T. Nzimande, and L. Zondi
Statisticians: A. C. Grobler, D. Taylor (FHI), L. Werner, and
N. Yende
Data Management: R. Lallbahadur, M. Mdladla, K. Naidoo,
T. Nala, C. Pillay, P. Sikakane, and T. Zondo
Quality Assurance: T. Govender, N. Mvandaba, F. van
Loggerenberg, and I. van Middelkoop
Laboratory: J. Naicker, V. Naranbhai, N. Ndlovu, N. Samsunder,
S. Sidhoo, P. Tshabalala, J. Ledwaba (NICD), and L.Morris (NICD),
Behavioral Science: J. Fisher (University of Connecticut) and
K. MacQueen (FHI)
Cohort Coordinators: L. R. Luthuli and F. Ntombela
Cohort Administrators: P. F. Chonco, D. P. Magagula, P. C.
Majola, T. Ndlovu, L. Ngobese, N. Ngubane, and N. M. Zwane
Community Outreach: N. Bhengu, P. Buthelezi, P. D.
Lembethe, B. F. Mazibuko, S. F. Mdluli, W. N. Mkhize, S. P.
Ndlovu, S. Ngubane, R. M. Ogle, and R. B. Xulu
Administrative Staff: N. Amla, S. A. Barnabas, T. Malembe,
M. Matthews, Y. T. Miya, A. Mqadi, S. Panday, S. Sibisi, M.






14 June 2010; accepted 13 July 2010
Published online 20 July 2010;
10.1126/science.1193748
Include this information when citing this paper.
3 SEPTEMBER 2010 VOL 329 SCIENCE www.sciencemag.org1174
RESEARCH ARTICLES
 o
n 
S
ep
te
m
be
r 
6,
 2
01
0 
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fr
om
 
